Loading...

Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 163.42 USD -0.7% Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one JNJ stock under the Base Case scenario is 138.09 USD. Compared to the current market price of 163.42 USD, Johnson & Johnson is Overvalued by 15%.

The Intrinsic Value is calculated as the average of the two valuation methods:

JNJ Intrinsic Value
Base Case
138.09 USD
Overvaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

JNJ Profitability Score
Profitability Due Diligence

Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.

Declining ROE
Positive 1-Year Revenue Growth
Positive Revenue Growth Forecast
ROIC is Increasing
66/100
Profitability
Score

Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.

JNJ Solvency Score
Solvency Due Diligence

Johnson & Johnson's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Short-Term Liabilities
Negative Net Debt
Long-Term Liabilities
Low D/E
78/100
Solvency
Score

Johnson & Johnson's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
67%
Gross Margin
26%
Operating Margin
19%
Net Margin
19%
FCF Margin
25%
ROE
15%
ROIC
Other

JNJ Capital Structure
Johnson & Johnson

Market Capitalization 428B USD
Total Debt 31.5B USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 5.6B USD
Short-Term Investments 28.5B USD
Enterprise Value 425B USD

Wall St
Price Targets

JNJ Price Targets Summary
Johnson & Johnson

Wall Street analysts forecast JNJ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JNJ is 188.75 USD with a low forecast of 161.6 USD and a high forecast of 225.75 USD.

Lowest
Price Target
161.6 USD
1% Downside
Average
Price Target
188.75 USD
16% Upside
Highest
Price Target
225.75 USD
38% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

JNJ Competitors
Johnson & Johnson

JNJ Suppliers & Customers
Johnson & Johnson

Johnson & Johnson has 171 key suppliers from 18 countries and 28 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
95
Emergent BioSolutions Inc
Biotechnology
Omnicom Group Inc
Media
Ampco-Pittsburgh Corp
Metals & Mining
Jabil Inc
Electrical Equipment
Bristol-Myers Squibb Co
Pharmaceuticals
Abbvie Inc
Biotechnology
Dynatrace Inc
Technology
Model N Inc
Technology
Quotient Technology Inc
Retail
Catalent Inc
Pharmaceuticals
Invitae Corp
Health Care
Bright Horizons Family Solutions Inc
Diversified Consumer Services
O
ON24 Inc
Technology
Boston Scientific Corp
Health Care
Graphic Packaging Holding Co
Packaging
Barnes Group Inc
Machinery
Live Nation Entertainment Inc
Media
IQVIA Holdings Inc
Life Sciences Tools & Services
Informatica Inc
Technology
Aptargroup Inc
Packaging
Exagen Inc
Biotechnology
C
Cue Health Inc
Health Care
Gilead Sciences Inc
Biotechnology
Blink Charging Co
Electrical Equipment
F-Star Therapeutics Inc
Biotechnology
Matthews International Corp
Commercial Services & Supplies
Ligand Pharmaceuticals Inc
Biotechnology
Socket Mobile Inc
Technology
Matrix Service Co
Construction
Amgen Inc
Biotechnology
Altimmune Inc
Biotechnology
R
Royalty Pharma PLC
Pharmaceuticals
V
Viant Technology Inc
Technology
Viatris Inc
Pharmaceuticals
D
Definitive Healthcare Corp
Health Care
Sprout Social Inc
Technology
Minerva Neurosciences Inc
Biotechnology
MacroGenics Inc
Biotechnology
F
Fate Therapeutics Inc
Biotechnology
IZEA Worldwide Inc
Media
Scholar Rock Holding Corp
Biotechnology
Calumet Specialty Products Partners LP
Energy
Halozyme Therapeutics Inc
Biotechnology
Veracyte Inc
Biotechnology
Digimarc Corp
Technology
Vaxart Inc
Biotechnology
Momentive Global Inc
Technology
X
Xencor Inc
Biotechnology
Protagonist Therapeutics Inc
Biotechnology
P
Pulmatrix Inc
Pharmaceuticals
V
Vor Biopharma Inc
Biotechnology
Certara Inc
Health Care
Provention Bio Inc
Pharmaceuticals
Anika Therapeutics Inc
Biotechnology
Guardant Health Inc
Health Care
MeiraGTx Holdings PLC
Biotechnology
B
Beam Global
Electrical Equipment
Arcturus Therapeutics Holdings Inc
Biotechnology
N
NN Inc
Machinery
Progress Software Corp
Technology
B
Biodesix Inc
Health Care
Kaleido Biosciences Inc
Pharmaceuticals
CRA International Inc
Professional Services
Silgan Holdings Inc
Packaging
R C M Technologies Inc
Professional Services
Luna Innovations Inc
Electrical Equipment
Transcat Inc
Trading Companies & Distributors
Nektar Therapeutics
Pharmaceuticals
T
TRACON Pharmaceuticals Inc
Biotechnology
Cidara Therapeutics Inc
Biotechnology
Dyadic International Inc
Biotechnology
X
Xcel Brands Inc
Retail
Genocea Biosciences Inc
Biotechnology
P
Pro-Dex Inc
Health Care
S
Stagwell Inc
Media
Myriad Genetics Inc
Biotechnology
Legend Biotech Corp
Biotechnology
S
Sema4 Holdings Corp
Health Care
X
XOMA Corp
Biotechnology
Harvard Bioscience Inc
Life Sciences Tools & Services
Morphic Holding Inc
Biotechnology
Microsoft Corp
Technology
Poseida Therapeutics Inc
Biotechnology
Sotherly Hotels Inc
Real Estate
C
Cass Information Systems Inc
Technology
Universal Stainless & Alloy Products Inc
Metals & Mining
Arrowhead Pharmaceuticals Inc
Biotechnology
XBiotech Inc
Biotechnology
Mersana Therapeutics Inc
Biotechnology
Mastermind Inc
Media
E
Encision Inc
Health Care
Glatfelter Corp
Paper & Forest
A
Apeiron Capital Investment Corp
N/A
F
Fathom Digital Manufacturing Corp
Machinery
SpringWorks Therapeutics Inc
Biotechnology
Suppliers Map

Johnson & Johnson has 61 key customers from 12 countries and 10 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Customers Map

Ownership

JNJ Insider Trading
Buy and sell transactions by insiders

Johnson & Johnson insiders have only sold shares in the past 12 months.

During the last 12 months Johnson & Johnson insiders have not bought any shares, and sold 81.3M USD worth of shares. The last transaction was made on Feb 6, 2023 by Wolk Joseph J (Exec VP, CFO), who sold 2.7M USD worth of JNJ shares.

Sold
0-3
months
34.9M USD
5
3-6
months
31M USD
2
6-9
months
8.4M USD
2
9-12
months
7M USD
2
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
34.9M USD
N/A
-34.9M
6 Months
65.9M USD
N/A
-65.9M
9 Months
74.4M USD
N/A
-74.4M
12 Months
81.3M USD
N/A
-81.3M
Purchases
24
Sales
158
No transactions found
Why is insider trading important?

Shareholder Return

JNJ Price
Johnson & Johnson

1M 1M
-9%
6M 6M
-3%
1Y 1Y
-3%
3Y 3Y
+14%
5Y 5Y
+41%
Annual Price Range
163.42
52w Low
156.08
52w High
183.59
Price Metrics
Average Annual Return 9.88%
Standard Deviation of Annual Returns 7.55%
Max Drawdown -27%
Shares Statistics
Market Capitalization 428B USD
Shares Outstanding 2 614 479 872
Percentage of Shares Shorted 0.48%

Company Profile

Johnson & Johnson

Country

United States of America

Industry

Pharmaceuticals

Market Cap

428B USD

Dividend Yield

2.76%

Description

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 141,700 full-time employees. The firm operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.

Contact

NEW JERSEY
New Brunswick
One Johnson & Johnson Plaza
+17325242455.0
https://www.jnj.com/

IPO

1944-09-25

Employees

141 700

Officers

Exec. Chairman
Mr. Alex Gorsky
CEO & Director
Mr. Joaquin Duato
Exec. VP & CFO
Mr. Joseph J. Wolk CPA
Exec. VP & Worldwide Chairman of Pharmaceuticals
Ms. Jennifer L. Taubert
Controller & Chief Accounting Officer
Mr. Robert J. Decker Jr.
Exec. VP & Chief Information Officer
Mr. James Swanson
Show More
VP of Investor Relations
Ms. Jessica Moore
Chief Compliance Officer
Mr. Dirk Brinckman
Exec. VP & Gen. Counsel
Ms. Elizabeth Forminard
Exec. VP & Chief HR Officer
Dr. Peter M. Fasolo Ph.D.
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one JNJ stock?

The intrinsic value of one JNJ stock under the Base Case scenario is 138.09 USD.

Is JNJ stock undervalued or overvalued?

Compared to the current market price of 163.42 USD, Johnson & Johnson is Overvalued by 15%.